MX2023004078A - Proteinas f de hmpv estabilizadas por prefusion. - Google Patents

Proteinas f de hmpv estabilizadas por prefusion.

Info

Publication number
MX2023004078A
MX2023004078A MX2023004078A MX2023004078A MX2023004078A MX 2023004078 A MX2023004078 A MX 2023004078A MX 2023004078 A MX2023004078 A MX 2023004078A MX 2023004078 A MX2023004078 A MX 2023004078A MX 2023004078 A MX2023004078 A MX 2023004078A
Authority
MX
Mexico
Prior art keywords
proteins
hmpv
prefusion
stabilized
engineered
Prior art date
Application number
MX2023004078A
Other languages
English (en)
Inventor
Jason Mclellan
Ching - Lin HSIEH
Nianshuang Wang
Scott Rush
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2023004078A publication Critical patent/MX2023004078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan proteínas F de hMPV modificadas. En algunos aspectos, las proteínas F modificadas exhiben estabilidad conformacional y/o antigenicidad mejoradas. También se proporcionan métodos para el uso de las proteínas F modificadas como diagnóstico, en plataformas de detección y/o en composiciones de vacunas.
MX2023004078A 2020-10-09 2021-10-07 Proteinas f de hmpv estabilizadas por prefusion. MX2023004078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089978P 2020-10-09 2020-10-09
PCT/US2021/053944 WO2022076669A1 (en) 2020-10-09 2021-10-07 Prefusion-stabilized hmpv f proteins

Publications (1)

Publication Number Publication Date
MX2023004078A true MX2023004078A (es) 2023-05-24

Family

ID=81125547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004078A MX2023004078A (es) 2020-10-09 2021-10-07 Proteinas f de hmpv estabilizadas por prefusion.

Country Status (12)

Country Link
US (2) US11919927B2 (es)
EP (1) EP4225364A1 (es)
JP (1) JP2023544834A (es)
KR (1) KR20230084201A (es)
CN (1) CN116615235A (es)
AU (1) AU2021357826A1 (es)
CA (1) CA3195015A1 (es)
CO (1) CO2023005373A2 (es)
IL (1) IL301950A (es)
MX (1) MX2023004078A (es)
PE (1) PE20231439A1 (es)
WO (1) WO2022076669A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240133A1 (es) 2020-11-13 2024-01-30 Icosavax Inc Vacuna de nanoparticula a base de proteinas contra metapneumovirus
WO2023110618A1 (en) * 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023217988A1 (en) * 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
KR20220139415A (ko) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
EP3236998A1 (en) * 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
CN112243444A (zh) * 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
MX2021013111A (es) 2019-05-20 2021-11-17 Valneva Se Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.
US20230174587A1 (en) 2020-04-29 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human metapneumovirus f proteins and their use
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins

Also Published As

Publication number Publication date
JP2023544834A (ja) 2023-10-25
AU2021357826A1 (en) 2023-05-11
CA3195015A1 (en) 2022-04-14
WO2022076669A1 (en) 2022-04-14
AU2021357826A9 (en) 2023-07-13
US20240140994A1 (en) 2024-05-02
PE20231439A1 (es) 2023-09-14
CN116615235A (zh) 2023-08-18
IL301950A (en) 2023-06-01
CO2023005373A2 (es) 2023-05-19
KR20230084201A (ko) 2023-06-12
US20230357327A1 (en) 2023-11-09
EP4225364A1 (en) 2023-08-16
US11919927B2 (en) 2024-03-05

Similar Documents

Publication Publication Date Title
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
MX2023004078A (es) Proteinas f de hmpv estabilizadas por prefusion.
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
ATE476196T1 (de) Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
AR054937A1 (es) Goma de mascar biodegradable
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
WO2007024941A3 (en) Polyvalent vaccine
DE602005014628D1 (de) Embolie-teilchen
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
ATE518012T1 (de) Isolate des das reproduktions- und atemwegssyndrom verursachenden schweinevirus und ihre verwendung
MX339060B (es) Formulaciones del factor viii.
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
MX2019004464A (es) Cerdos que comprenden cd163 modificada y metodos asociados.
MX2021004477A (es) Componentes recombinantes y composiciones para usarse en productos alimenticios.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
ATE453328T1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
BRPI0613362A8 (pt) polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CY1108521T1 (el) Παρασκευη αλδεσλευκινης για φαρμακευτικη χρηση
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX2022014161A (es) Vacunas contra sars-cov-2.